Haemonetics Corporation (NYSE:HAE) – Research analysts at Barrington Research lifted their FY2018 earnings estimates for Haemonetics Corporation in a report released on Wednesday. Barrington Research analyst M. Petusky now forecasts that the medical instruments supplier will post earnings per share of $1.68 for the year, up from their previous estimate of $1.65. Barrington Research currently has a “Outperform” rating and a $57.00 price target on the stock. Barrington Research also issued estimates for Haemonetics Corporation’s Q4 2018 earnings at $0.45 EPS and FY2020 earnings at $2.00 EPS.

A number of other equities research analysts have also recently issued reports on the company. JMP Securities raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research report on Thursday, July 13th. BidaskClub cut Haemonetics Corporation from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 27th. Jefferies Group LLC reaffirmed a “buy” rating and set a $48.00 target price on shares of Haemonetics Corporation in a research report on Thursday, July 27th. TheStreet raised Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Finally, Zacks Investment Research raised Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $51.33.

WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/11/10/fy2018-earnings-estimate-for-haemonetics-corporation-hae-issued-by-barrington-research.html.

Haemonetics Corporation (HAE) traded down $0.40 during midday trading on Thursday, reaching $54.52. The company’s stock had a trading volume of 695,177 shares, compared to its average volume of 344,364. The firm has a market cap of $2,860.00, a P/E ratio of 33.26, a PEG ratio of 4.06 and a beta of 0.91. Haemonetics Corporation has a 12-month low of $36.44 and a 12-month high of $55.10. The company has a current ratio of 2.17, a quick ratio of 1.72 and a debt-to-equity ratio of 0.22.

Haemonetics Corporation (NYSE:HAE) last issued its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.07. The company had revenue of $225.40 million during the quarter, compared to the consensus estimate of $219.12 million. Haemonetics Corporation had a net margin of 0.50% and a return on equity of 11.16%. Haemonetics Corporation’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the company earned $0.38 EPS.

A number of institutional investors have recently bought and sold shares of the stock. US Bancorp DE boosted its holdings in Haemonetics Corporation by 0.6% in the second quarter. US Bancorp DE now owns 22,154 shares of the medical instruments supplier’s stock valued at $875,000 after acquiring an additional 141 shares during the last quarter. Tudor Investment Corp ET AL boosted its holdings in Haemonetics Corporation by 0.5% in the second quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock valued at $1,111,000 after acquiring an additional 143 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in Haemonetics Corporation by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 21,400 shares of the medical instruments supplier’s stock valued at $845,000 after acquiring an additional 200 shares during the last quarter. Rothschild Asset Management Inc. boosted its holdings in Haemonetics Corporation by 0.3% in the second quarter. Rothschild Asset Management Inc. now owns 87,858 shares of the medical instruments supplier’s stock valued at $3,470,000 after acquiring an additional 269 shares during the last quarter. Finally, Strs Ohio boosted its holdings in Haemonetics Corporation by 1.0% in the second quarter. Strs Ohio now owns 29,300 shares of the medical instruments supplier’s stock valued at $1,157,000 after acquiring an additional 300 shares during the last quarter.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Earnings History and Estimates for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.